| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K50799972 | CTRPv2 | pan-cancer | AAC | 0.0064 | 0.9 |
| mRNA | ouabain | CTRPv2 | pan-cancer | AAC | -0.0059 | 0.9 |
| mRNA | JNJ-26854165 | CTRPv2 | pan-cancer | AAC | 0.0058 | 0.9 |
| mRNA | L-685458 | CCLE | pan-cancer | AAC | 0.0076 | 0.9 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.0049 | 0.9 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | 0.0056 | 0.9 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0052 | 0.9 |
| mRNA | STF-62247 | GDSC1000 | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | BRD-K34099515 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.9 |
| mRNA | rigosertib | CTRPv2 | pan-cancer | AAC | -0.0052 | 0.9 |